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In this issue of Cancer Cell, Arozarena et al. describe that the oncogenic BRAF Val600Glu mutant, which
occurs in about half of melanomas, downregulates the cGMP-hydrolysing phosphodiesterase PDE5A in
melanoma cells through the ERK-MAPK cascade coupled to the POU-domain transcription factor BRN2,
thereby increasing intracellular cGMP levels and promoting invasiveness.Melanocytes provide critical protection of
skin from ultraviolet radiation. However,
gene mutations can lead to malignant
cutaneous melanoma, whose incidence
is on the increase. Although surgical
removal of the tumor provides an effective
first line therapy, progression occurs in
around 20% of cases to an aggressive,
metastasizing form of the disease with
extremely poor patient survival rates.
Nearly half of all melanomas carry an acti-
vating mutation in BRAF, one of the three
forms of the RAF protein kinase family
activated by Ras in the ERKprotein kinase
pathway that promotes cell proliferation.
Ninety percent of such BRAF mutations
involve a change of the hydrophobic
Val600 for a negatively charged Glu,
identifying activated Val600Glu-BRAF as
a potential therapeutic target (Bollag
et al., 2010).
The Val600Glu-BRAF oncogene
causes the upregulation of a large cohort
of genes in melanoma cells and, intrigu-
ingly, the downregulation of a much
more restricted set (Packer et al., 2009).
Recently, Marais and colleagues (Arozar-
ena et al., 2011) have provided an
extremely exciting and novel insight into
the critical issue of melanoma cell inva-
siveness, discovering that it can be eli-
cited by the downregulation of PDE5A
(Figure 1), a cyclic nucleotide phosphodi-
esterase that specifically hydrolyses the
second messenger, cGMP (Francis
et al., 2009). Active-site directed selective
inhibitors of this enzyme are used acutely
for the treatment of penile erectile
dysfunction (PED) and infantile hyperten-
sion (Francis et al., 2009). It has also
been suggested that chronic application
of PDE5 selective inhibitors may havepotential for treating leukemia, colorectal
carcinoma, and breast cancer (see, e.g.,
Zhu et al., 2005), although recent studies
have questioned whether PDE5 is the
target (Abadi et al., 2010), as well as for
treating heart failure (Kass et al., 2007).
Eleven cyclic nucleotide phosphodies-
terase (PDE) families provide over 70
distinct proteins that hydrolyze either or
both the second messengers, cAMP and
cGMP (Conti and Beavo, 2007). The
impressive diversity of this super family
reflects their ability to provide key nodes
for cross-talk between signaling path-
ways via both distinct regulatory domains
and posttranslational modification
through phosphorylation, ubiquitination,
and SUMOylation (Houslay, 2010). Criti-
cally, various PDEs possess targeting
sequences for sequestration by scaffold
and other proteins into ‘‘signalosomes,’’
conferring signal compartmentalization
through spatial regulation of cyclic nucle-
otide degradation (Houslay, 2010).
The PDE5A gene locates to human
chromosome 4q25-27 and encodes three
kinetically identical variants distinguished
by distinct N-terminal regions (Francis
et al., 2009). The functional role for iso-
form diversity is unknown. However, their
tissue distribution varies considerably,
and it is possible that the distinct
N-terminal regions are involved in target-
ing PDE5A isoforms to distinct signaling
complexes, as occurs with PDE4 iso-
forms (Houslay, 2010). PDE5 isoforms
exhibit twin GAF domains, which repre-
sent one of the largest and most wide-
spread of the small-molecule binding
domains found in nature. The GAF A
domain binds cGMP and facilitates the
PKG/PKA-dependent phosphorylationCancer Celland activation of PDE5. Structural studies
show that the two N-terminal GAF A
domains interact with each other and
may serve to stabilize a PDE5 dimer.
Importantly, however, the PDE5 catalytic
unit is the target for various highly selec-
tive competitive inhibitors used to treat
PED, namely Viagra, Zydena, Cialis, and
Levitra. Thesecompoundsexert a relaxing
effect on the vasculature of the penis; but
this occurs only in the presence of an
external neuronal or endothelial stimulus
that can promote increased nitric oxide
generation. Thus, nitric oxide activates
guanylyl cyclase, causing cGMP pro-
duction that is amplified by inhibitor
blockade of PDE5-mediated cGMP de-
gradation. Elevated cGMP levels acti-
vate PKG, which phosphorylates several
substrates in smooth muscle, such as
Ca2+-activated maxi K+ (BKCa) channels,
IRAG (IP3 receptor associated cGMP
kinase substrate), and the regulatory
myosin-binding subunit of myosin phos-
phatase, that lead to a reduction in
intracellular Ca2+ and, consequently, to
smooth muscle relaxation.
Marais and colleagues (Arozarena
et al., 2011) now uncover a hitherto
unforeseen role for PDE5A in controlling
the invasiveness of melanoma cells.
They demonstrate that oncogenic, acti-
vated BRAF acts through MEK and the
POU-domain transcription factor BRN2
to downregulate PDE5A. This leads to
a rise in cGMP, which causes elevation
of intracellular Ca2+ levels and a dramatic
and consequential increase in melanoma
cell invasion that depends upon
increased myosin light chain 2 (MLC2)
phosphorylation. Thus, enhanced cGMP/
Ca2+ -regulated actin-myosin contractility19, January 18, 2011 ª2011 Elsevier Inc. 3
Figure 1. PDE5A Downregulation in Val600Glu-BRAF-Expressing
Melanoma Cells Promotes Invasiveness
Schematic showing that expression of oncogenic Val600Glu-BRAF activates
the ERK-MAPK pathways leading to upregulation of the BRN-2 transcription
factor, which suppresses transcription of the PDE5A gene. Downregulation
of PDE5A lowers cGMP degradation, causing an increase in intracellular
cGMP levels. These elicit an increase in intracellular Ca2+, which triggers the
phosphorylation of myosin light chain 2, causing a contraction-induced shape
change and increase in invasiveness.
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Previewsis essential for invasion
induced by PDE5A downre-
gulation. This observation
was very surprising because,
in vascular smooth muscle
cells, cGMP elicits relaxation,
indicating that the ‘‘wiring’’
associated with cGMP
signaling is very different in
melanoma cells. They went
on to confirm the pivotal role
of PDE5A in this process, as
ectopic expression of any
PDE5A isoform suppressed
the invasiveness of Val600-
Glu-BRAF-expressing mela-
noma cells. Furthermore,
they found that PDE5A was
downregulated in a substan-
tial collection of melanoma
lines expressing oncogenic
BRAF, indicating that this is
an inherent phenotype and
may provide a biomarker for
enhanced invasiveness andpoor prognostic outcome. Indeed, in this
regard, primary tumors showed higher
overall PDE5A expression than did meta-
static tumors. PDE5 downregulation was
also clearly specific to BRAF mutant
melanoma cells, as it was not evident in
either NRAS mutant melanoma cells or
BRAF mutant colorectal cells. The
absence of PKG isoforms (PRKG1 and
PRKG2) in melanoma cells may explain
why loss of PDE5 does not confer relaxa-
tion, as the cGMP-activated kinase,
PRKG1, mediates relaxation by cGMP in
vascular smooth muscle cells (Weber
et al., 2007).
Interestingly, Marais and colleagues
found that in a melanoma cell line
where PDE5A was not so strongly down-
regulated, inhibition of either MEK or
Val600Glu-BRAF led to PDE5A upregula-
tion and decreased invasiveness. This
prompted them to question whether inhi-
bition of PDE5 might promote an invasive
phenotype in Val600Glu-BRAF-express-
ing melanoma cells where PDE5A was
not fully downregulated. Indeed, this
proved to be the case, with PDE5 inhibi-
tion promoting both in vitro and in vivo
increased invasiveness of a Val600Glu-
BRAF-expressing melanoma cell line
where, although downregulated, signi-
ficant PDE5A was still expressed.
However, PDE5 selective inhibitors did
not promote invasiveness in Val600Glu-4 Cancer Cell 19, January 18, 2011 ª2011 ElBRAF- expressing melanoma cells where
PDE5 expression was ablated. These
data imply that means to upregulate
PDE5A selectively in Val600Glu-BRAF-
expressing melanoma cells may have
therapeutic potential in preventing
metastases.
Many questions remain to be resolved:
one is the mechanism through which one
of the ten Val600Glu-BRAF-containing
melanoma cell lines investigated still
showed significant PDE5 expression.
Additionally, analyses of an extensive
number of Val600Glu-BRAF-containing
melanomas are needed to determine
whether the particular melanoma cell line
identified in these studies reflects an
‘‘oddity’’ where, normally, all oncogenic
B-RAF melanomas are indeed PDE5A
null and thus insensitive to any potential
invasiveness-promoting effect that might
be conferred through PDE5 inhibition.
Investigations are also required to
determine whether in Val600Glu-BRAF-
expressing melanoma cells having
residual PDE5A, chronic PDE5 inhibition
is required to potentiate their invasiveness
or whether acute PDE5 inhibition can
suffice. It will also be important to deter-
mine whether such cells express other
cGMP-hydrolyzing PDEs and, if so,
whether their inactivation also promotes
invasiveness or whether this phenotype
is solely determined by a ‘‘pool’’ ofsevier Inc.cGMP that is specifically
controlled by PDE5A.
Certainly, such compartmen-
talization coupled to distinct
phenotypic responses has
been well characterized for
cAMP pools determined by
distinct PDE forms (Houslay,
2010). Finally, it will be of
interest to determine whether
PDE5 inhibition increases
invasiveness of melanoma
cells that do not express the
mutant Val600Glu-BRAF or
whether such a specific back-
ground is required for this
action. Clearly these are
important issues that require
further investigation.
This elegant study thus
provides an important insight
into the mechanism whereby
oncogenic B-RAF promotes
invasiveness in melanoma
cells through a mechanismthat pivotally involves PDE5A downregu-
lation and elevation of cGMP levels
(Figure 1).REFERENCES
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